A Study of LY317615 in Patients With Brain Tumors | NCT00190723 | Trialant
CompletedInterventionalPhase 2Updated Jan 26, 2007
A Study of LY317615 in Patients With Brain Tumors
A Phase II Trial of LY317615 in Patients With Recurrent High-Grade Gliomas
ClinicalTrials.gov ID
NCT00190723
Lead Sponsor
Eli Lilly and CompanyINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
120
Last Update Posted
Jan 26, 2007Estimated
Start Date
Oct 2002
Completion Date
Dec 2006
Official Title
A Phase II Trial of LY317615 in Patients With Recurrent High-Grade Gliomas
Brief Summary
The safety of LY317615 and any side effects that might be associated with the drug.
Whether LY317615, can help patients with brain tumors.
Malignant Glioma
Enzastaurin
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
You must be at least 18 years old
You must have been diagnosed with a recurrent brain tumor by MRI or CT scan
You must be able to swallow the LY317615 tablets
Exclusion Criteria:
You are a woman who is pregnant or breastfeeding
In view of your doctor, you have significant heart, liver, kidney, or psychiatric disease
Primary Purpose
Treatment
Allocation
Non-Randomized
Interventional Model
Single Group Assignment
Masking
None (Open Label)
No central contacts
There are no central contacts for this study.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician